AC-1101

Phase 1Small molecule

TTWi Biotechnology, Inc.

AC-1101 is one of 3 small molecule programs targeting Granuloma Annulare. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Granuloma AnnulareActive, not recruiting

Granuloma AnnularePhase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Granuloma Annulare

#DrugCompanyPhaseTrials

Cibinqo

Pfizer

Phase 2

1 2

Xeljanz

PPrism Pharmaceuticals

Phase 1

1 3

AC-1101

TTWi Biotechnology, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Granuloma Annulare1 trial

Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare

Completed·TTWi Biotechnology, Inc.·Phase 1·NCT05580042·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AC-1101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AC-1101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AC-1101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TWi Biotechnology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTWi Biotechnology, Inc.

AC-1101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Granuloma Annulare1 trial

References

Drug Info

Quick Facts

Related News